Skip to content

Post-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE

ANCRAGE: Post-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06940934
Acronym
ANCRAGE PMS
Enrollment
100
Registered
2025-04-23
Start date
2021-12-01
Completion date
2027-04-30
Last updated
2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysms

Brief summary

The aims of this clinical data collection are to investigate mortality, morbidity and neurological outcome 12 months after treatment of subject's intracranial aneurysm(s) and additionally to evaluate potential residual risks associated with the use of the commercial device(s) and to ensure the long-term safety and performance of Acandis Device(s) after its placing on the French market. On top of this, these cohorts will generate data for getting the renewal of the device's reimbursement on the French market.

Interventions

None listed

Sponsors

Acandis GmbH
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject has an intracranial aneurysm that can be treated with one of the Acandis device indicated for the treatment of intracranial aneurysms. * The subject is 18 years of age or older. * The subject is willing to comply with scheduled visits and examinations, per institution standard of care.

Exclusion criteria

* The subject has provided tacit opposition to data collection. * Any IFU warning will be considered for exclusion in the cohort.

Design outcomes

Primary

MeasureTime frameDescription
Morbi-mortality related to the device and/or procedure at 12+/-3 months post implantation12+/-3 months after treatmentMorbi-mortality related to the device and/or procedure at 12+/-3 months post implantation, defined as a mRS \>/= 3 for the subjects with a baseline mRS between 0 and 2 or mRS increase of 1 point for subjects with a baseline mRS greater than 2.

Countries

France

Contacts

Primary ContactAcandis GmbH
clinicalaffairs@acandis.com+49 7231 980 84 0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026